Why Head and Neck Cancer Rehab Trials Must Stratify for Lymphoedema

Survival after head and neck cancer has improved steadily over recent decades, but the price of that progress is increasingly visible in the daily lives of survivors. Among the least discussed and most under-researched consequences of treatment is lymphoedema, the chronic swelling that develops when surgery and radiotherapy disrupt lymphatic drainage in the face, neck, and throat. A new correspondence published in Supportive Care in Cancer by Asmaa Abou-Bakr of Galala University and Fatma E. A. Hassanein of King Salman International University argues that the rehabilitation research field has reached a turning point: feasibility studies alone are no longer enough, and future trials must be designed with lymphoedema status built into their very architecture.

The correspondence, published on 16 September 2026, responds directly to the CaRe feasibility study, a head and neck cancer rehabilitation trial published earlier in the same journal in June 2026 by Sheill and colleagues. Feasibility studies occupy a crucial niche in clinical research. They test whether a trial can actually be done: whether patients will enrol, whether clinicians can deliver the intervention consistently, whether outcome measures are tolerable and interpretable, and whether attrition stays within acceptable limits. The CaRe study did exactly this work for a structured rehabilitation programme in head and neck cancer, laying the groundwork that larger definitive trials require.

Yet Abou-Bakr and Hassanein contend that a trial can pass every feasibility benchmark and still fail to answer the questions that matter most to patients, if it treats all head and neck cancer survivors as a single homogeneous group. Their central argument is that lymphoedema is not a minor comorbidity to be averaged out in randomisation; it is a distinct clinical entity that changes what rehabilitation should look like, what outcomes are realistic, and how success should be measured. Pooling patients with and without lymphoedema, they suggest, risks diluting treatment effects and obscuring the very signals that a definitive trial is designed to detect.

The clinical case for stratification rests on a growing body of evidence about what head and neck lymphoedema actually does to patients. A 2026 systematic review by Gaitatzis and colleagues in the Journal of Cancer Survivorship examined patient-reported outcome measures and physical function following head and neck lymphoedema and documented the breadth of its impact. Unlike limb lymphoedema, which is visible and relatively straightforward to measure with circumference or volume techniques, lymphoedema in the head and neck region affects structures that govern speech, swallowing, breathing, and appearance. Internal lymphoedema, involving the pharynx and larynx, can be invisible from the outside while profoundly impairing function.

The burden extends well beyond physical symptoms. Research by Starmer and colleagues, published in Supportive Care in Cancer in 2023, captured the patient perspective on head and neck lymphoedema and quality of life, revealing how swelling reshapes identity, social interaction, and emotional wellbeing. A 2024 study by Arends and colleagues in the journal Cancers added further weight, showing that lymphoedema and trismus, the restriction of jaw opening that frequently accompanies treatment, have a measurable impact on body image and quality of life after head and neck cancer. For a population already coping with disfigurement, altered speech, and compromised swallowing, lymphoedema compounds the challenge of returning to a recognisable life.

Against this backdrop, the evidence base for treating head and neck lymphoedema remains strikingly thin. A 2025 systematic review by de-la-Cruz-Fernández and colleagues in Supportive Care in Cancer assessed randomised controlled trials of physical therapy interventions for lymphoedema management in this population and found the available trials limited in number and scope. This scarcity is precisely why feasibility work such as the CaRe study matters, and equally why the field cannot afford to design its definitive trials carelessly. If the few large trials that eventually emerge fail to account for lymphoedema status, an entire generation of rehabilitation evidence may be built on foundations too heterogeneous to support firm conclusions.

The argument for lymphoedema-stratified trial design has technical dimensions that go beyond simple subgroup analysis. Stratification in randomised trials means that patients are grouped by a key prognostic characteristic before randomisation, ensuring that treatment and control arms are balanced for that characteristic. In the context of head and neck cancer rehabilitation, stratifying by lymphoedema presence, severity, or type, external versus internal, would allow investigators to estimate whether rehabilitation produces different benefits in patients whose lymphatic systems have been compromised. It would also permit pre-specified subgroup analyses that are powered and planned from the outset, rather than the underpowered post hoc explorations that have historically plagued rehabilitation research.

Measurement is another pillar of the argument. Trials that ignore lymphoedema may choose outcome instruments that are insensitive to the changes that matter most to affected patients. The systematic review by Gaitatzis and colleagues highlighted the state of patient-reported outcome measures in this space, and the correspondence implicitly raises the question of whether generic quality-of-life instruments can capture the specific distress of facial and neck swelling, or whether lymphoedema-specific measures should be embedded in trial design. A rehabilitation programme might improve general physical function while leaving a patient’s lymphoedema-related body image concerns untouched, a result that a poorly designed trial would misread as partial success rather than a targeted failure.

The broader context of head and neck cancer survivorship strengthens the case further. Studies of rehabilitation needs, including work by Karampela and colleagues published in Frontiers in Oncology in 2021, have documented gaps between what patients require and what services deliver, while a 2025 systematic review by Bernstein and colleagues catalogued the social impacts of treatment and rehabilitation in this population. Head and neck cancer survivors face some of the highest rates of depression, social withdrawal, and functional impairment in oncology, and rehabilitation is the discipline charged with restoring what treatment takes away. Designing rehabilitation trials that reflect the true clinical heterogeneity of the population is therefore not a methodological nicety; it is a prerequisite for evidence that translates into meaningful care.

Abou-Bakr and Hassanein’s correspondence, written without specific funding and with no declared competing interests, functions as a call to action for trialists in supportive and rehabilitative cancer care. The message is that the field has demonstrated it can run rehabilitation studies in head and neck cancer; the CaRe feasibility study and its predecessors have answered the operational questions. The next step demands more ambition: definitive trials in which lymphoedema is not an afterthought but a design principle, with stratified randomisation, lymphoedema-sensitive outcome measures, and analyses planned to reveal which patients benefit most from which interventions. For the growing population of head and neck cancer survivors living with swelling that affects how they speak, swallow, and see themselves in the mirror, the difference between a generic rehabilitation trial and a lymphoedema-stratified one could ultimately determine whether the evidence that guides their care is sharp enough to help them.

Subject of Research: Lymphoedema-stratified rehabilitation trial design in head and neck cancer survivorship

Article Title: Beyond feasibility: the case for lymphoedema-stratified rehabilitation trials in head and neck cancer

Article References: Abou-Bakr, A., & Hassanein, F. E. A. (2026). Beyond feasibility: the case for lymphoedema-stratified rehabilitation trials in head and neck cancer. Supportive Care in Cancer, 34(10), Article 977. https://doi.org/10.1007/s00520-026-11222-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11222-8

Keywords: head and neck cancer, lymphoedema, cancer rehabilitation, clinical trial design, stratification, feasibility study, quality of life, supportive care, physical therapy, trismus, patient-reported outcomes, cancer survivorship